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Purpose: The photoreceptor-specific orphan nuclear receptor NR2E3 is a key regulator of transcriptional events during
photoreceptor differentiation in mammalian retina. Mutations in NR2E3 are associated with enhanced S-cone syndrome
and related retinal phenotypes that reveal characteristic excess of S-cone function. This study was undertaken to determine
biochemical as well as functional consequences of reported sequence variants and disease-causing mutations in NR2E3.
Methods: Twenty-five different mutations in the wild-type NR2E3 expression construct were generated by site-directed
mutagenesis  and  performed  nuclear  localization,  gel-shift,  rhodopsin  promoter  activity  assays,  and  co-
immunoprecipitation in cultured mammalian cells.
Results: Of the 25 mutant proteins, 15 mislocalize at least partially to the cytoplasm. Eight of the nine changes in the
DNA-binding domain (DBD) and 12 of the 14 mutations in the ligand-binding domain (LBD) of NR2E3 exhibited reduced
DNA-binding and transcriptional activation of the rhodopsin promoter. Moreover, these mutations dramatically altered
the interaction of NR2E3 with NRL as well as with CRX. Two NR2E3 variants between DBD and LBD showed no effect
on any biochemical or functional parameter tested.
Conclusions: These data provide a better understanding of sequence variants, validate disease-causing mutations, and
demonstrate the significance of DBD and LBD in mediating NR2E3 function. These studies contribute to molecular
mechanisms underlying retinal phenotypes caused by NR2E3 mutations.
Retinal diseases represent a major cause of untreatable
blindness  in  developed  countries.  Despite  extensive
phenotypic  and  genetic  heterogeneity,  these  disorders
primarily  affect  photoreceptor  function  [1-3]  (RetNet
website).  Enhanced  S-cone  syndrome  (ESCS;  OMIM
268100) is a rare and somewhat unusual form of autosomal
recessive retinal disease; the clinical characteristics include
night  blindness,  an  abnormal  electroretinogram  with  a
waveform that is nearly identical under both light and dark
adaptation, an increased sensitivity of the electroretinogram
to  short-wavelength  light,  cystoid  maculopathy,  and
degenerative  changes  of  the  vascular  arcades  [4-8].  The
altered ratio of S- to L/M-cone photoreceptor sensitivity in
ESCS was suggested to be due to abnormal cone cell fate
determination during retinal development [8]. ESCS is caused
by  mutations  in  a  photoreceptor-specific  nuclear  receptor
nuclear receptor subfamily 2 group E member 3 (NR2E3, also
called PNR; OMIM 604485) [9].
NR2E3 was initially identified through a search of genes
related to NR2E1 (also called TLX or tailless) [10] and shown
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to be expressed in retinal photoreceptors [9,11,12]. A large
number of sequence variants as well as possible mutations in
NR2E3 have been reported in patients with ESCS and other
retinal  phenotypes,  which  include  autosomal  dominant
retinitis  pigmentosa  (ADRP),  autosomal  recessive  RP
(ARRP), Bardet-Biedl syndrome (BBS), clumped pigmentary
retinal degeneration (CPRD), cone-rod dystrophy (CORD),
and Goldmann-Favre syndrome (GFS) [9,13-24]. Consistent
with the human phenotypes, a loss of function mutation in
Nr2e3, caused by a L1 insertion, leads to increased S-cone
function, slow degeneration of photoreceptors, and abnormal
lamination of the outer nuclear layer with rosette formation in
the retinal degeneration 7 (rd7) mouse [25,26]. While NR2E3
is suggested to be involved in controlling cone proliferation
[27,28],  overwhelming  evidence  has  established  NR2E3
primarily as a transcriptional suppressor of cone genes [12,
29-32].  Moreover,  NR2E3  is  downstream  of  the  rod
differentiation factor neural retina leucine zipper (NRL) in
transcriptional regulatory hierarchy [33] and can activate rod-
specific genes (such as rhodopsin) synergistically with NRL
or cone-rod homeobox (CRX) [12].
The analysis of NR2E3 primary sequence reveals two
distinct regions: DNA-binding domain (DBD) close to the N-
terminus, and ligand-binding domain (LBD) at the C-terminus
[10]; a vast majority of human NR2E3 variants/mutations are
detected in these two domains (Figure 1A). Though the effect
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2174of a few has been evaluated [31,34,35], a comprehensive
analysis of many variants and mutations has not been reported.
This  investigation  was  undertaken  to  distinguish  NR2E3
variants and polymorphisms from disease-causing mutations
based on biochemical and functional parameters. Here, we
describe the impact of 25 distinct sequence changes on NR2E3
protein  localization,  DNA-binding  activity,  transcriptional
activation of rhodopsin promoter, and interaction with NRL
and CRX.
METHODS
Cell culture and transfection studies: COS-1 and HEK293
cells  purchased  from  ATCC  were  cultured  in  Dulbecco’s
modified Eagle’s medium containing 10% fetal bovine serum.
Transient  transfections  of  plasmid  DNA  were  performed
using FuGENE 6 (Roche Applied Science, Indianapolis, IN)
at 80% cell confluency.
Plasmid constructs and mutagenesis: The wild-type (WT)
human  NR2E3  cDNA  (GenBank  NM_014249.2)  was
subcloned at EcoRI–NotI sites in the pcDNA4 His/Max C
vector  (Invitrogen,  Carlsbad,  CA)  [12].  All  mutants  were
generated by QuickChange XL site-directed mutagenesis kit
(Stratagene, La Jolla, CA). The V5 epitope tag sequence was
added at C-terminus of the pED-NRL and -CRX constructs
[36] by site-direct mutagenesis. The pED expression vector is
a derivative of pMT3 (Genetics Institute, Cambridge, MA).
All constructs were sequence-verified before use.
Immunoblotting  and  immunocytochemistry:  COS-1  cells
harbor large T-antigen and are suitable for transfection by
vectors requiring expression of SV40 T-antigen. This allows
expression  of  higher  amount  of  protein  for  immunoblot
Figure 1. A schematic diagram of the human NR2E3 protein. A: Arrows indicate altered NR2E3 residues. Abbreviations: DNA binding domain
(DBD), ligand binding domain (LBD), nuclear localization signal (NLS; NM_014249.2). B: NR2E3 protein sequence aligned to orthologs.
By using ClustalW, we were able to align the sequence of human NR2E3 protein with those of chimp, rhesus, cow, mouse, opossum, chicken,
frog, fugu, zebrafish, tetraodon, honeybee, mosquito, fruitfly, and roundworm. Amino acid residues conserved in all orthologs are indicated
by asterisk, and lower identity or similarity is shown using either colon or a dot. Shadows indicate NR2E3 mutations analyzed in this report.
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2175analysis,  immunoprecipitation,  and  immunocytochemistry.
COS-1 cell extracts were solubilized in SDS-lysis buffer (2%
SDS,  10%  Glycerol,  0.062M  Tris-HCl  pH  6.8,  0.005%
Bromophenol Blue) by heating to 100 °C for 5 min. Twenty
μg  proteins  were  separated  by  12%  SDS–PAGE  and
transferred to nitrocellulose by electroblotting. Immunoblot
analysis  was  performed  using  a  mouse  monoclonal  anti-
Xpress  antibody  (Invitrogen),  and  immunostaining  was
performed essentially as described [37]. Briefly, COS-1 cells
were transfected with plasmid DNA expressing WT or mutant
NR2E3 protein. The cells were incubated with anti-Xpress
antibody, followed by a secondary anti-mouse IgG Alexa
fluor  488  (Invitrogen).  Nuclei  were  counterstained  with
bisbenzimide.
Electrophoretic  mobility  shift  assay:  Gel  shift  assays
(EMSAs) were performed as described [10,29]. Briefly, the
expression of the mutant NR2E3 protein in transfected COS-1
cell extracts was normalized by immunoblot analysis. The
labeled probe DNA was initially incubated for 30 min on ice
in binding buffer containing 10 mM Tris (pH 8.0), 1 mM DTT,
0.1% Nonidet P-40, 7.5% glycerol, and 0.1 mg/ml of poly(dI-
dC). The Kni x2 oligonucleotides were Fw 5′-AGC TTA ACC
CTT TTA AAA GTC AAA AGT CAA CTT CCA ACA
GCT-3′; and Rv 5′-AGC TGT TGG AAG TTG ACT TTT
GAC TTT TAA AAG GGT TAA GCT-3′. The nonspecific
oligonucleotides were Fw 5′-AGC TTA ACC CTT TTA AAA
TTC AAA ATT CAA CTT CCA ACA GCT-3′; and Rv 5′-
AGC TGT TGG AAG TTG AAT TTT GAA TTT TAA AAG
GGT TAA GCT-3′. Kni is derived from a TLL/TLX binding
site found in the upstream region of Drosophila melanogaster
knirps  gene  [10].  For  competition  experiments,
nonradiolabeled oligonucleotides were used in 50 fold molar
excess of the labeled oligonucleotides. Samples were loaded
on  a  5%  nondenaturing  polyacrylamide  gel.  After
electrophoresis, gels were dried and exposed to X-ray film.
Luciferase assays: HEK293 cells were used for luciferase
reporter assays to allow relatively lower protein expression,
thereby  assisting  in  the  evaluation  of  differences  in
transcriptional  activities  of  mutant  proteins.  Luciferase
reporter assays were performed using HEK293 cells, pGL2
with  the  bovine  rhodopsin  promoter  driving  a  luciferase
cDNA (BR130-luc), and expression vectors containing WT-
CRX  cDNA  (pcDNA4-CRX)  and  NRL  cDNA  (pcDNA-
NRL), as described [37]. The plasmid DNA expressing WT
or mutant NR2E3 protein was cotransfected with pBR130-luc
and  pcDNA4-CRX  as  well  as  pcDNA4-NRL.  Empty
pcDNA4  expression  vector  and  CMV-β-galactosidase
plasmids were also included to normalize for the amount of
transfected DNA and transfection efficiency, respectively. All
transfections were performed in triplicate and repeated at least
three times.
Immunoprecipitation: WT or variant/mutant NR2E3 plasmid
constructs were cotransfected into COS-1 cells with pED-
NRL-V5 or -CRX-V5. The cells were harvested in 1× PBS
containing protease inhibitors (Roche Applied Science). After
an initial incubation of sonicated cell extracts with Protein-G
beads (Invitrogen), goat anti-V5 antibody (Applied Biologic
Materials Inc., BC, Canada) was added and left overnight at
4 °C with gentle mixing. The beads were washed with 1× PBS
containing  1%  Triton  X-100,  suspended  in  SDS  sample
buffer, and analyzed by SDS–PAGE.
RESULTS
Human NR2E3 variants and mutations: To date, almost 50
NR2E3  sequence  changes  (possible  disease-causing
mutations or polymorphic variations) have been reported in
patients with ESCS, ADRP, ARRP, BBS, CPRD, CORD, and
GFS [9,13-23]; of these, we have evaluated the following in
this report: 22 missense (p.G56R [c.166G>A], p.R76Q [c.
225G>A],  p.R76W  [c.226C>T],  p.G88V  [c.263G>T],
p.R97H  [c.290G>A],  p.R104Q  [c.311G>A],  p.R104W  [c.
310C>T],  p.E121K  [c.361G>A],  p.E140G  [c.419G>A],
p.M163T  [c.488T>C],  p.V232I  [c.694G>A],  p.W234S  [c.
701G>C],  p.A256E  [c.767C>A],  p.L263P  [c.788T>C],
p.V302I  [c.904G>A],  p.R309G  [c.925C>G],  p.R311Q  [c.
932G>A],  p.R334G  [c.1000C>G],  p.L336P  [c.1007T>C],
p.L353V [c.1057G>A], p.R385P [c.1154G>C] and p.M407K
[c.1220T>A])  mutations,  one  nonsense  (p.Q350X  [c.
1048C>T]), one deletion (p.N65_C67del [c.194_202del9]),
and  one  frameshift  (p.P276fs  [c.827_843del17])  change
(Figure 1A). The NR2E3 sequence is highly conserved during
evolution (Ensemble). Residues G88, R97, R104, E121, and
M407 are conserved in all NR2E3 orthologs from human to
roundworm, whereas G56, N65, G66, C67, R76, and W234
are detected in all except tetradon (Figure 1B).
Effect of NR2E3 mutations on subcellular localization: We
generated  aforementioned  25  mutations  in  WT-NR2E3
expression  construct  and  expressed  the  WT  and  mutant
proteins  in  COS-1  cells.  All  mutant  proteins  displayed  a
predicted band size (45 kDa + 4 kDa Xpress epitope) upon
immunoblot analysis, except two—p.P276fs and p.Q350X—
because of premature truncation (data not shown). The WT-
NR2E3 protein was detected in the nucleus of transfected
COS-1 cells (Figure 2), consistent with nuclear localization
of NR2E3 in rod photoreceptors of human and mouse retina
[11,12].  Most  mutations  in  NR2E3  (p.R76Q,  p.R76W,
p.R97H, p.W234S, p.A256E, p.L263P, p.P276fs, p.R309G,
p.R311Q, p.R334G, p.L336P, p.Q350X, p.L353V, p.R385P,
and p.M407K) resulted in partial or complete mislocalization
of the expressed protein to the cytoplasm (Figure 2 and Table
1).
Effect  of  NR2E3  mutations  on  DNA-binding:  The  target
sequence  for  binding  of  NR2E3  has  not  been  described;
however, a synthetic DNA including two AAGTCA half-sites
separated by one spacer nucleotide (Kni x2) could bind to
NR2E3 [10]. Kni is derived from a TLL/TLX binding site
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knirps gene [10]. Extracts from NR2E3-transfected COS-1
cells but not from untransfected or mock-transfected cells
could bind to Kni x2 probe in EMSAs (Figure 3A). The
intensity  of  shifted  band  was  reduced  by  an  excess  of
unlabeled  Kni  x2  oligonucleotide,  but  not  nonspecific
oligonucleotide (Figure 3A), as reported previously [10,29].
EMSA  with  p.V232I,  p.W234S,  p.V302I,  p.R311Q,  and
p.R334G mutant proteins exhibit reduced binding to Kni x2
oligonucleotide compared to the WT. Several other mutants
(p.N65_C67del,  p.R76Q,  p.R76W,  p.R97H,  p.R104Q,
p.R104W, p.A256E, p.L263P, p.P276fs, p.R309G, p.L336P,
p.Q350X, p.L353V, and p.R385P) showed no specific DNA
binding (Figure 3B), even with a 10-fold molar excess of the
transfected cell protein (data not shown). A faint signal was
observed with p.G56R mutant protein in contrast to a recent
study  [35],  probably  because  of  different  DNA  binding
conditions  as  well  as  cell  lines  used.  Another  report  had
revealed similar results with some of the mutants we studied
(p.W234S, p.R311Q, p.385P, and p.407K) [34].
The NR2E3 protein expressed in COS-1 cells did not
show binding to a predicted NR2E3 binding sites in the bovine
rhodopsin  promoter  (data  not  shown),  as  these  sequences
(GAG CCA CGA GTC G or GCC TCA GAA GCA T) are
somewhat different from the consensus (AAG TCA NAA
GTC A) used in EMSA. It is possible that NR2E3 binding to
rhodopsin promoter is mediated via its interaction with NRL
or CRX [12].
Effect of mutations on transcriptional activity of NR2E3: We
used luciferase reporter activity assays to examine whether
mutations  affect  the  transcriptional  regulatory  activity  of
NR2E3 on bovine rhodopsin promoter. As reported earlier
[12], NR2E3 synergistically activates the rhodopsin promoter
through  its  interaction  with  NRL  and  CRX  (Figure  3C).
Mutations  in  the  DBD  (p.G56R,  p.N65_C67del,  p.R76Q,
p.R76W,  p.G88V,  p.R97H,  p.R104Q,  and  p.R104W)  and
LBD  (p.A256E,  p.L263P,  p.P276fs,  p.V302I,  p.R309G,
p.R311Q, p.R334G, p.L336P, p.Q350X, p.L353V, p.R385P,
and p.M407K) demonstrated a variable reduction in NR2E3-
mediated  increase  in  transcriptional  activity  when  mutant
NR2E3 construct was cotransfected with both NRL and CRX
Figure 2. Subcellular localization of WT and mutant NR2E3 proteins in COS-1 cells. COS-1 cells expressing WT or mutant NR2E3 proteins
were incubated with anti-Xpress antibody (anti-Xp) and visualized using anti-mouse IgG-Alexa 488 antibody (green). Central panels show
nuclei labeled with bisbenzimide (blue). The bottom panels display merged images. Scale bar represents 50 μm.
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or CRX was used with mutant NR2E3 (data not shown). The
data using R76W, R97H, and M407K mutants were consistent
with previous studies [29,31]. The p.W234S and p.R311Q
mutants showed different results from those reported [13,31],
probably due to the differences in cell lines used as well as the
length of bovine rhodopsin promoter.
Effect of mutations and variants on the interaction of NR2E3
with NRL and CRX: NR2E3 interacts directly with NRL and
CRX  [12,31].  We  therefore  used  cotransfection  and
coimmunoprecipitation assays to further evaluate the effect of
mutations  in  DBD  and  LBD  on  the  ability  of  NR2E3  to
interact with NRL or CRX. The variations and mutations
residing between DBD and LBD did not show any change in
various assays; hence this study focused only on mutations in
DBD and LBD. Reduced interaction with NRL is observed
with  p.W234S,  p.A256E,  p.L263P,  p.P276fs,  p.V302I,
p.R309G, p.R311G, p.R334G, p.L336P, p.Q350X, p.L353V,
p.R385P, and p.M407K mutants (Figure 4A). The p.G56R,
p.N65_C67del,  p.R97H,  p.R104Q,  p.E121K,  p.A256E,
p.L263P, p.P276fs, p.V302I, p.R309G, p.R311G, p.R334G,
p.L336P,  p.Q350X,  p.L353V,  p.R385P,  and  p.M407K
mutations in NR2E3 revealed decreased interaction with CRX
(Figure 4B).
DISCUSSION
Mutations in over 150 genes are associated with inherited
retinal  dysfunction  as  well  as  degeneration  [2]  (RetNet
website). These genes encode proteins with diverse cellular
functions,  including  phototransduction,  intracellular
transport,  and  transcriptional  regulation.  NRL,  CRX,  and
NR2E3  are  key  transcription  factors  that  regulate
photoreceptor differentiation, and mutations in these lead to
retinopathies  [9,36,38,39].  We  undertook  this  study  to
distinguish bona fide disease-causing mutations in NR2E3
from  polymorphic  variants  based  on  biochemical  and
functional parameters and to examine the structure-function
relationship (see Table 2 for a comprehensive summary). We
show that mutations in the DBD and LBD of the NR2E3
protein  result  in  functional  changes  and  are  likely  to  be
disease-causing.
TABLE 1. SUBCELLULAR LOCALIZATION OF MUTANT NR2E3 PROTEINS.
Amino acid change Nuclear (%) Nuclear and cytoplasmic (%) Cytoplasmic (%)
WT 97 2.7 0.3
p.G56R 95.3 3.7 1
p.N65_C67del 89.3 9 1.7
p.R76Q 56.7 29 14.3
p.R76W 52.5 26.8 20.7
p.G88V 90.5 6.3 3.2
p.R97H 59.5 29.2 11.3
p.R104Q 90.8 8 1.2
p.R104W 90.5 6 3.5
p.E121K 94.5 5 0.5
p.E140G 92.5 5.8 1.7
p.M163T 95.2 3.5 1.3
p.V232I 94.5 4.8 0.7
p.W234S 29.5 54.7 15.8
p.A256E 28.5 63.2 8.3
p.L263P 27.2 60.3 12.5
p.P276fs 13.5 79.7 6.8
p.V302I 92 6.2 1.8
p.R309G 83.5 15 1.5
p.R311Q 70.3 25.2 4.5
p.R334G 71.2 22.8 6
p.L336P 14.5 72 13.5
p.Q350X 5.5 80 14.5
p.L353V 5.5 74.2 20.3
p.R385P 35.2 58 6.8
p.M407K 38 59 3
Cellular localization of WT and mutant NR2E3 proteins was examined in COS-1 cells after transfection with the expression
construct. Mutations affecting NR2E3 nuclear localization (p.R76Q, p.R76W, p.R97H, p.W234S, p.A256E, p.L263P, p.P276fs,
p.R309G, p.R311Q, p.R334G, p.L336P, p.Q350X, p.L353V, p.R385P, and p.M407K) demonstrate increased cytoplasmic
staining. More than 200 cells were scored from at least two independent immunocytochemistry experiments.
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2178In NR2E3-DBD, a proximal box (P-box; residues 65 to
69) and a distal box (D-box; residues 84 and 90) bind to the
half-site  core  sequence  (AAGTCA)  and  are  critical  for
determining  DNA-binding  specificity  and  dimerization,
whereas the T-box region (residues 114 to 130) makes a helix
and correlates to a dimerization surface [10,40]. Although
Coppieters et al. [19] suggested a putative nuclear localization
signal between residues 72 and 78 in NR2E3, our data show
that a single amino acid change in the nuclear localization
signal is not sufficient to change the cellular localization of
NR2E3.  The  p.N65_C67del  mutant  lacks  three  residues
(Asn-65, Gly-66, Cys-67) in the P-box. Mutations in highly
conserved residues at position 56, 97, and 104 that are located
within the zinc finger region involved in DNA binding [41]
affect transcriptional activity. Interestingly, the changes at
residues 56 and 104 reduced the interaction of NR2E3 with
CRX  but  not  NRL,  probably  because  of  altered  protein
interaction surfaces. These studies suggest that the nature of
interactions  between  NR2E3  and  NRL  or  CRX  and  the
conformation of the DBD of NR2E3 could be critical for
differential regulation of gene expression in photoreceptors.
Crystal structures of retinoid X receptor-α (RXRα) reveal
that LBD in nuclear receptors consists of 12 α-helices (H1 to
H12) [42,43]. The region from H3 to H4 contains a LBD-
specific  signature  motif  [(F/W)AKxxxFxxLxxxDQxxLL]
that is involved in dimerization and transactivation and holds
together H3–5, H8, and H9 [44,45]. Trp-234 is one of the
residues constructing the signature motif, and as expected,
p.W234S mutation leads to the loss of NR2E3 function, as in
case of a similar estrogen receptor-α mutation [46]. Mutations
in  Val-302  and  Arg-311  residues  that  are  expected  to
participate in anchoring interactions between helices [42,47]
appear to affect NR2E3 function in the assays we used. The
dimerization interface is mainly located in H9 and H10 [42],
Figure 3. Effect of NR2E3 mutations on DNA binding and transactivation. A: EMSAs were performed using the [32P]-labeled Kni x2 probe
with untransfected (UnTR) COS-1 cells or WT NR2E3 expressing cell extracts. Specificity of DNA binding is demonstrated by competition
with unlabeled Kni x2 oligonucleotide (50×) and nonspecific (NS) oligonucleotide (50×). The arrow indicates the position of a specific DNA–
protein complex between NR2E3 and Kni x2 oligonucleotide. B: Binding of mutant NR2E3 proteins to the labeled Kni x2 oligonucleotide
was examined by EMSA. Mutant NR2E3 protein amount in cell extracts was normalized to WT-NR2E3 by immunoblot analysis. C: NR2E3
expression constructs were cotransfected into HEK293 cells with bovine rhodopsin-130 luciferase reporter plasmid and with NRL and CRX
expression constructs. Fold change is relative to the empty expression vector control. Error bars indicate standard error of mean (SE). D:
Luciferase assays were performed after co-transfection of mutant NR2E3 construct with the NRL and/or CRX expression constructs. ANOVA
with a post hoc test were performed on each sample compared to WT NR2E3. Significant differences of p<0.05, and p<0.01 are shown as *
and **, respectively. Error bars correspond to SEM.
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2179suggesting  that  p.L353V  and  p.R385P  mutants  in  these
regions may impair dimerization. Met-407 is located within
H12, which covers the ligand-binding cavity and stabilizes
ligand binding by contributing to the hydrophobic pocket
[43]. Substitution of Leu-263 (H5) and Leu-336 (loop 8–9) to
Proline  completely  eliminated  NR2E3  function,  probably
because of altered NR2E3 conformation [16]. The p.P276fs
and p.Q350X mutations are completely missing the latter half
part of the LBD, thereby resulting in a loss of function. Other
mutations (p.A256E of H5, p.R309Q of H7, p.R334G of loop
8–9) decreased the ability of NR2E3 to interact with NRL and
CRX.  As  co-activators  are  necessary  for  ligand-activated
nuclear receptors to stimulate transcription [48], amino acid
substitutions in NR2E3 helices or loops that selectively affect
interaction with NRL as well as CRX are expected to alter
transcriptional regulation of downstream genes. Most of the
alterations in the LBD exhibited reduced DNA binding. This
mutant fused to Gal4-DBD was previously reported to impair
transcriptional suppression [29]. We hypothesize that certain
LBD residues in NR2E3 contribute to unique structural motifs
or participate in dimerization, and mutations at these sites may
alter  interactions  resulting  in  weaker  or  diminished  DNA
binding. The significant role of LBD in NR2E3 functions
implicates as a yet to be determined ligand that may control
NR2E3 activity in rod photoreceptors.
The p.E121K mutation in the T-box within DBD and
p.V232I change in LBD-H3, together with two variations
detected between DBD and LBD (p.E140G and p.M163T),
demonstrated no effect on biochemical as well as functional
parameters that we have tested. Notably, p.E140G, p.M163T,
and p.V232I variants were detected in BBS and RP patients
as well as in control individuals [9]. The p.E121K mutation
was identified in an ESCS patient and is located within the T-
box  [10].  These  data  reveal  that  p.E140G,  p.M163T,  and
Figure 4. Interaction of WT and mutant
NR2E3 proteins with NRL or CRX. A:
Xpress-tagged  WT  or  mutant  NR2E3
expression plasmids were cotransfected
into COS-1 cells with V5-tagged NRL
expression  construct.  After
immunoprecipitation with goat anti-V5
antibody, NR2E3 protein was detected
with  mouse  anti-Xpress  antibody.  B:
NR2E3  expression  constructs  were
cotransfected into COS-1 cells with V5-
tagged  CRX  expression  construct.
NR2E3 was visualized with mouse anti-
Xpress antibody. In lower panels, the
intensity  of  the  WT  NR2E3
immunoreactive  band  (normalized  to
input  NR2E3)  was  compared  with
mutant NR2E3 proteins. ANOVA with
a post hoc test were performed on each
sample  compared  to  WT  NR2E3.
Significant differences of p<0.05, and
p<0.01  are  shown  as  *  and  **,
respectively.
Molecular Vision 2009; 15:2174-2184 <http://www.molvis.org/molvis/v15/a234> © 2009 Molecular Vision
2180T
A
B
L
E
 
2
.
 
A
 
S
U
M
M
A
R
Y
 
O
F
 
E
F
F
E
C
T
S
 
O
F
 
V
A
R
I
A
N
T
S
 
O
N
 
N
R
2
E
3
 
F
U
N
C
T
I
O
N
P
r
o
b
a
n
d
d
i
a
g
n
o
s
i
s
N
u
c
l
e
o
t
i
d
e
c
h
a
n
g
e
*
A
m
i
n
o
 
a
c
i
d
c
h
a
n
g
e
*
A
l
l
e
l
e
s
R
e
f
e
r
e
n
c
e
I
B
S
u
b
c
e
l
l
u
l
a
r
l
o
c
a
l
i
z
a
t
i
o
n
B
i
n
d
i
n
g
 
t
o
K
n
i
 
x
2
R
h
o
-
p
 
L
u
c
 
w
i
t
h
N
R
L
+
C
R
X
)
I
n
t
e
r
a
c
t
i
o
n
 
(
N
R
L
/
C
R
X
)
E
f
f
e
c
t
-
W
i
l
d
 
t
y
p
e
-
-
-
+
N
u
c
+
+
+
/
+
-
A
D
R
P
c
.
1
6
6
G
>
A
p
.
G
5
6
R
p
.
G
5
6
R
/
+
1
9
N
o
 
c
h
a
n
g
e
N
u
c
D
o
w
n
D
o
w
n
S
i
m
i
l
a
r
/
D
o
w
n
M
u
t
E
S
C
S
/
G
F
S
c
.
1
9
4
_
2
0
2
d
e
l
9
p
.
N
6
5
_
C
6
7
d
e
l
c
.
I
V
S
1
–
2
A
>
C
/
p
.
N
6
5
_
C
6
7
d
e
l
9
N
o
 
c
h
a
n
g
e
N
u
c
D
o
w
n
D
o
w
n
S
i
m
i
l
a
r
/
D
o
w
n
M
u
t
E
S
C
S
c
.
2
2
5
G
>
A
p
.
R
7
6
Q
p
.
R
7
6
Q
/
+
9
N
o
 
c
h
a
n
g
e
N
u
c
,
 
C
y
t
D
o
w
n
D
o
w
n
S
i
m
i
l
a
r
/
S
i
m
i
l
a
r
M
u
t
E
S
C
S
c
.
2
2
6
C
>
T
p
.
R
7
6
W
p
.
R
7
6
W
/
+
9
N
o
 
c
h
a
n
g
e
N
u
c
,
 
C
y
t
D
o
w
n
D
o
w
n
S
i
m
i
l
a
r
/
S
i
m
i
l
a
r
M
u
t
E
S
C
S
c
.
2
6
3
G
>
T
p
.
G
8
8
V
p
.
G
8
8
V
/
p
.
G
8
8
V
1
6
N
o
 
c
h
a
n
g
e
N
u
c
D
o
w
n
D
o
w
n
S
i
m
i
l
a
r
/
S
i
m
i
l
a
r
M
u
t
E
S
C
S
c
.
2
9
0
G
>
A
p
.
R
9
7
H
p
.
R
9
7
H
/
p
.
R
9
7
H
9
N
o
 
c
h
a
n
g
e
N
u
c
,
 
C
y
t
D
o
w
n
D
o
w
n
S
i
m
i
l
a
r
/
D
o
w
n
M
u
t
E
S
C
S
c
.
3
1
1
G
>
A
p
.
R
1
0
4
Q
p
.
R
1
0
4
Q
/
p
.
R
3
3
4
G
1
7
N
o
 
c
h
a
n
g
e
N
u
c
D
o
w
n
D
o
w
n
S
i
m
i
l
a
r
/
D
o
w
n
M
u
t
E
S
C
S
c
.
3
1
0
C
>
T
p
.
R
1
0
4
W
c
.
I
V
S
1
–
2
A
>
C
/
p
.
R
1
0
4
W
9
N
o
 
c
h
a
n
g
e
N
u
c
D
o
w
n
D
o
w
n
N
D
M
u
t
E
S
C
S
c
.
3
6
1
G
>
A
p
.
E
1
2
1
K
p
.
E
1
2
1
K
/
+
9
N
o
 
c
h
a
n
g
e
N
u
c
S
i
m
i
l
a
r
S
i
m
i
l
a
r
S
i
m
i
l
a
r
/
D
o
w
n
U
n
c
B
B
S
/
R
P
c
.
4
1
9
G
>
A
p
.
E
1
4
0
G
p
.
E
1
4
0
G
/
+
9
N
o
 
c
h
a
n
g
e
N
u
c
S
i
m
i
l
a
r
S
i
m
i
l
a
r
N
D
V
a
r
B
B
S
/
R
P
c
.
4
8
8
T
>
C
p
.
M
1
6
3
T
p
.
M
1
6
3
T
/
+
9
N
o
 
c
h
a
n
g
e
N
u
c
S
i
m
i
l
a
r
S
i
m
i
l
a
r
N
D
V
a
r
B
B
S
/
R
P
c
.
6
9
4
G
>
A
p
.
V
2
3
2
I
p
.
V
2
3
2
I
/
+
9
N
o
 
c
h
a
n
g
e
N
u
c
D
o
w
n
S
i
m
i
l
a
r
D
o
w
n
/
S
i
m
i
l
a
r
V
a
r
E
S
C
S
c
.
7
0
1
G
>
C
p
.
W
2
3
4
S
p
.
W
2
3
4
S
/
+
9
N
o
 
c
h
a
n
g
e
N
u
c
,
 
C
y
t
D
o
w
n
D
o
w
n
D
o
w
n
/
S
i
m
i
l
a
r
M
u
t
C
P
R
D
c
.
7
6
7
C
>
A
p
.
A
2
5
6
E
c
.
I
V
S
1
–
2
A
>
C
/
p
.
A
2
5
6
E
1
4
N
o
 
c
h
a
n
g
e
N
u
c
,
 
C
y
t
D
o
w
n
D
o
w
n
D
o
w
n
/
D
o
w
n
M
u
t
E
S
C
S
c
.
7
8
8
T
>
C
p
.
L
2
6
3
P
c
.
I
V
S
1
–
2
A
>
C
/
p
.
L
2
6
3
P
1
6
N
o
 
c
h
a
n
g
e
N
u
c
,
 
C
y
t
D
o
w
n
D
o
w
n
D
o
w
n
/
D
o
w
n
M
u
t
C
P
R
D
c
.
8
2
7
_
8
4
3
d
e
l
1
7
p
.
P
2
7
6
f
s
c
.
I
V
S
1
–
2
A
>
C
/
p
.
P
2
7
6
f
s
1
4
N
o
 
c
h
a
n
g
e
N
u
c
,
 
C
y
t
D
o
w
n
D
o
w
n
D
o
w
n
/
D
o
w
n
M
u
t
B
B
S
/
R
P
c
.
9
0
4
G
>
A
p
.
V
3
0
2
I
p
.
V
3
0
2
I
/
+
9
N
o
 
c
h
a
n
g
e
N
u
c
D
o
w
n
D
o
w
n
D
o
w
n
/
D
o
w
n
U
n
c
E
S
C
S
c
.
9
2
5
C
>
G
p
.
R
3
0
9
G
p
.
R
3
0
9
G
/
p
.
R
3
1
1
Q
9
N
o
 
c
h
a
n
g
e
N
u
c
,
 
C
y
t
D
o
w
n
D
o
w
n
D
o
w
n
/
D
o
w
n
M
u
t
E
S
C
S
c
.
9
3
2
G
>
A
p
.
R
3
1
1
Q
p
.
R
3
1
1
Q
/
p
.
R
3
1
1
Q
9
N
o
 
c
h
a
n
g
e
N
u
c
,
 
C
y
t
D
o
w
n
D
o
w
n
D
o
w
n
/
D
o
w
n
M
u
t
E
S
C
S
c
.
1
0
0
0
C
>
G
p
.
R
3
3
4
G
p
.
R
1
0
4
Q
/
p
.
R
3
3
4
G
1
7
N
o
 
c
h
a
n
g
e
N
u
c
,
 
C
y
t
D
o
w
n
D
o
w
n
D
o
w
n
/
D
o
w
n
M
u
t
E
S
C
S
c
.
1
0
0
7
T
>
C
p
.
L
3
3
6
P
c
.
I
V
S
1
–
2
A
>
C
/
p
.
L
3
3
6
P
1
6
N
o
 
c
h
a
n
g
e
N
u
c
,
 
C
y
t
D
o
w
n
D
o
w
n
D
o
w
n
/
D
o
w
n
M
u
t
E
S
C
S
c
.
1
0
4
8
C
>
T
p
.
Q
3
5
0
X
p
.
Q
3
5
0
X
/
p
.
Q
3
5
0
X
1
5
N
o
 
c
h
a
n
g
e
N
u
c
,
 
C
y
t
D
o
w
n
D
o
w
n
D
o
w
n
/
D
o
w
n
M
u
t
E
S
C
S
c
.
1
0
5
7
G
>
A
p
.
L
3
5
3
V
c
.
4
8
1
d
e
l
A
/
p
.
L
3
5
3
V
1
6
N
o
 
c
h
a
n
g
e
N
u
c
,
 
C
y
t
D
o
w
n
D
o
w
n
D
o
w
n
/
D
o
w
n
M
u
t
E
S
C
S
c
.
1
1
5
4
G
>
C
p
.
R
3
8
5
P
p
.
R
3
8
5
P
/
+
9
N
o
 
c
h
a
n
g
e
N
u
c
,
 
C
y
t
D
o
w
n
D
o
w
n
D
o
w
n
/
D
o
w
n
M
u
t
E
S
C
S
c
.
1
2
2
0
T
>
A
p
.
M
4
0
7
K
p
.
M
4
0
7
K
/
p
.
M
4
0
7
K
9
N
o
 
c
h
a
n
g
e
N
u
c
,
 
C
y
t
S
i
m
i
l
a
r
D
o
w
n
D
o
w
n
/
D
o
w
n
M
u
t
T
h
e
 
r
e
s
u
l
t
s
 
o
f
 
n
u
c
l
e
a
r
 
l
o
c
a
l
i
z
a
t
i
o
n
,
 
E
M
S
A
,
 
l
u
c
i
f
e
r
a
s
e
 
a
s
s
a
y
s
 
a
n
d
 
i
m
m
u
n
o
p
r
e
c
i
p
i
t
a
t
i
o
n
s
 
f
o
r
 
e
a
c
h
 
m
u
t
a
t
i
o
n
 
a
r
e
 
s
u
m
m
a
r
i
z
e
d
 
i
n
 
t
h
i
s
 
t
a
b
l
e
.
 
E
a
c
h
 
a
l
t
e
r
a
t
i
o
n
 
i
s
 
c
a
t
e
g
o
r
i
z
e
d
a
s
 
a
 
m
u
t
a
t
i
o
n
,
 
v
a
r
i
a
t
i
o
n
 
o
r
 
c
h
a
n
g
e
 
o
f
 
u
n
c
e
r
t
a
i
n
 
s
i
g
n
i
f
i
c
a
n
c
e
 
b
a
s
e
d
 
o
n
 
t
h
e
 
e
x
p
e
r
i
m
e
n
t
s
 
r
e
p
o
r
t
e
d
 
i
n
 
t
h
i
s
 
s
t
u
d
y
.
 
A
b
b
r
e
v
i
a
t
i
o
n
s
:
 
r
e
t
i
n
i
t
i
s
 
p
i
g
m
e
n
t
o
s
a
 
(
R
P
)
,
 
a
u
t
o
s
o
m
a
l
d
o
m
i
n
a
n
t
 
R
P
 
(
A
D
R
P
)
,
 
B
a
r
d
e
t
-
B
i
e
d
l
 
s
y
n
d
r
o
m
e
 
(
B
B
S
)
,
 
c
l
u
m
p
e
d
 
p
i
g
m
e
n
t
a
r
y
 
r
e
t
i
n
a
l
 
d
y
s
t
r
o
p
h
y
 
(
C
P
R
D
)
,
 
e
n
h
a
n
c
e
d
 
S
-
c
o
n
e
 
s
y
n
d
r
o
m
e
 
(
E
S
C
S
)
,
 
G
o
l
d
m
a
n
n
-
F
a
v
r
e
s
y
n
d
r
o
m
e
 
(
G
F
S
)
,
 
m
u
t
a
t
i
o
n
 
(
M
u
t
)
,
 
n
o
 
d
a
t
a
 
(
N
D
)
,
 
c
y
t
o
p
l
a
s
m
 
(
C
y
t
)
,
 
n
u
c
l
e
a
r
 
(
N
u
c
)
,
 
u
n
c
e
r
t
a
i
n
 
s
i
g
n
i
f
i
c
a
n
c
e
 
(
U
n
c
)
,
 
v
a
r
i
a
t
i
o
n
 
(
V
a
r
)
,
 
r
h
o
d
o
p
s
i
n
 
p
r
o
m
o
t
e
r
 
d
r
i
v
i
n
g
 
l
u
c
i
f
e
r
a
s
e
(
R
h
o
-
p
 
L
u
c
)
.
 
*
T
h
e
 
m
u
t
a
t
i
o
n
 
n
o
m
e
n
c
l
a
t
u
r
e
 
u
s
e
s
 
t
h
e
 
f
i
r
s
t
 
n
u
c
l
e
o
t
i
d
e
 
o
f
 
t
h
e
 
A
T
G
 
c
o
d
o
n
 
i
n
 
t
h
e
 
c
D
N
A
 
(
N
M
_
0
1
4
2
4
9
.
2
)
 
a
s
 
+
1
,
 
a
n
d
 
t
h
e
 
f
i
r
s
t
 
c
o
d
o
n
 
o
f
 
t
h
e
 
p
r
o
t
e
i
n
 
a
s
 
+
1
(
N
M
_
0
1
4
2
4
9
.
2
)
.
Molecular Vision 2009; 15:2174-2184 <http://www.molvis.org/molvis/v15/a234> © 2009 Molecular Vision
2181p.V232I  are  not  likely  to  be  disease-causing  mutations;
however, additional experiments are required to validate the
association of p.E121K with retinal disease. It is possible that
mutations including p.E121K affect interaction with other
proteins  (e.g.,  NR1D1)  as  well  as  the  activity  of  other
promoters (e.g., Pde6b, Gnat1, S-opsin). However, one should
be cautious in interpreting the in vivo consequence of these
mutants as the studies reported here were performed in vitro.
So far, five homozygous mutations (p.G88V, p.R97H,
p.R311Q,  p.Q350X,  and  p.M407K)  and  15  compound
heterozygotes  (p.G56R,  p.N65_C67del,  p.R76Q,  p.R76W,
p.R104Q, p.R104W, p.W234S, p.A256E, p.L263P, p.P276fs,
p.R309G, p.R334G, p.L336P, p.L353V, and p.R385P) have
been reported in ESCS, ADRP, as well as CPRD probands.
Clinical investigations, together with this study, confirm that
all of these changes are disease-causing. In addition to 25
variants  tested  here,  three  additional  missense  mutations
(p.V49M,  p.Y81C,  and  p.A256V),  three  intron  splice-
acceptor mutations (IVS1–2A>C, IVS1–3C>G and IVS8–
1G>A),  and  a  one  base-pair  deletion  at  position  481  (c.
481delA), have been reported in ESCS patients [9,16,22].
IVS1–2A  is  among  the  most  common  NR2E3  mutations,
whereas 481delA causes a frameshift leading to 17 abnormal
residues followed by a premature stop codon. The p.S44L,
p.A63D, p.F71del, p.R77Q, p.G287S, p.K324R, p.K345X,
and p.Q350R mutations have also been reported in unaffected
controls and some retinopathy patients [18,19,23,24].
In  conclusion,  this  study  establishes  that  ESCS  and
related retinal phenotypes result from partial or complete loss
of  NR2E3  function  in  photoreceptors.  Disease-causing
NR2E3  mutations  are  associated  with  diminished
transcriptional regulatory activity, which can be due to altered
subcellular localization, reduced DNA binding or less-strong
interaction with co-regulators (such as NRL and CRX). Both
DBD and LBD are essential for NR2E3 function. The rd7
mouse offers an excellent model to investigate the mechanism
of disease caused by the loss of NR2E3 function [12,29]. We
hypothesize that (i) a lack of or reduced NR2E3 activity in
developing  retina  of  retinopathy  patients  does  not  allow
functional maturation of rod photoreceptors; (ii) enhanced S-
cone function is the result of de-repression of S-cone genes in
such photoreceptors; (iii) these abnormal rod photoreceptors
(expressing  cone  genes)  degenerate  with  time;  and  (iv)
different clinical phenotypes may reflect distinct impact of
mutations  on  the  transcriptional  regulatory  function  of
NR2E3.
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